{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-028296","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.346072+00:00","generated_at":"2026-05-16T12:43:22.274199+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cocrystal Pharma gets IRB approval for Phase 1b norovirus challenge study with CDI-988; enrollment starts Q1 2026","bullets":["IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.","Enrollment expected to begin Q1 2026; study involves up to 40 healthy subjects ages 18-49.","CDI-988 is first oral broad-spectrum antiviral for norovirus; no approved treatments or vaccines currently exist.","Study is randomized, double-blind, placebo-controlled; primary endpoint is reduction in clinical symptoms.","Follows prior FDA clearance of IND and favorable Phase 1 safety data from August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-028296","json":"https://secwatch.observer/filing/0001493152-25-028296.json","markdown":"https://secwatch.observer/filing/0001493152-25-028296.md","text":"https://secwatch.observer/filing/0001493152-25-028296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225028296/0001493152-25-028296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225028296/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:43:22.274199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}